The Cooper Companies, Inc. $COO Shares Sold by Forum Financial Management LP

Forum Financial Management LP reduced its position in The Cooper Companies, Inc. (NASDAQ:COO) by 9.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,913 shares of the medical device company’s stock after selling 520 shares during the period. Forum Financial Management LP’s holdings in Cooper Companies were worth $350,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of COO. Zions Bancorporation National Association UT acquired a new position in Cooper Companies during the 1st quarter worth approximately $33,000. GKV Capital Management Co. Inc. acquired a new position in Cooper Companies during the 1st quarter worth approximately $40,000. J.Safra Asset Management Corp lifted its position in Cooper Companies by 204.8% during the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after acquiring an additional 340 shares in the last quarter. Larson Financial Group LLC lifted its position in Cooper Companies by 1,071.0% during the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock worth $61,000 after acquiring an additional 664 shares in the last quarter. Finally, HM Payson & Co. lifted its position in Cooper Companies by 147.4% during the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock worth $75,000 after acquiring an additional 532 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Gerard H. Warner III acquired 1,450 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was purchased at an average cost of $69.23 per share, for a total transaction of $100,383.50. Following the purchase, the chief operating officer directly owned 18,319 shares in the company, valued at $1,268,224.37. This represents a 8.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were bought at an average price of $68.39 per share, with a total value of $136,780.00. Following the completion of the purchase, the director owned 5,777 shares in the company, valued at $395,089.03. The trade was a 52.95% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 17,975 shares of company stock worth $1,216,346 over the last 90 days. Insiders own 1.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Barclays assumed coverage on Cooper Companies in a research report on Monday, October 13th. They set an “overweight” rating and a $85.00 price target on the stock. Wells Fargo & Company reduced their price target on Cooper Companies from $93.00 to $72.00 and set an “overweight” rating on the stock in a research report on Thursday, August 28th. Robert W. Baird reduced their price target on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, August 28th. JPMorgan Chase & Co. cut their target price on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group set a $64.00 target price on Cooper Companies and gave the company a “sell” rating in a research report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Stock Performance

Shares of COO opened at $73.51 on Friday. The business’s 50 day moving average is $69.67 and its two-hundred day moving average is $73.25. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $108.32. The firm has a market cap of $14.61 billion, a price-to-earnings ratio of 36.21, a PEG ratio of 1.93 and a beta of 1.02. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.96 EPS. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a stock buyback program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to buy up to 15.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.